If you’re an innovator or inventor of small molecule and biologic therapeutics, you’ll need to protect your substantial investment in bringing a new product to market while making sure you are complying with all regulations.
Our lawyers have been integrating legal strategy with the commercial interests of our pharmaceutical clients for decades. We can help from start to finish of your invention, from product pipeline IP freedom to operate strategies, IP protection and litigation, clinical trials, licensing, marketing and advertising, and product development and supply agreements.
Pharma and biotech is second nature to us. Many of our people have technical degrees and backgrounds in chemistry and life sciences, as well as law degrees, meaning we understand both the science and the law surrounding your innovations.
Drawing on this experience, we will work closely with you to help achieve your business and financial goals through licensing and other monetization. We can also help you develop offensive and defensive Hatch-Waxman and Biosimilars strategies and facilitate cooperation, as we recently did between some major pharma clients and a large non-profit organization seeking to battle tuberculosis.
Ultimately, we know how to protect your IP and what regulators are looking for in every jurisdiction across the globe. Our aim is to get your drugs and biotech out into the world, working and healing.
Our global team has years of experience working with pharma and biotech companies just like yours. Our recent experience includes:
- having hundreds of technologies and inventions under our care and protection including small molecule synthesis and polymorph purification, antibody design and recombinant production, stabilizing and delayed-release formulations, oral dosage and injectable formulations, drug delivery devices (e.g., microneedles, patches and implants), combination drug and medical device products, alternative indications, and routes of administration
- acting on a landmark pharma case, which defined the scope of sponsor pension obligations in Ireland
- assisting an early stage pharma company focusing on antiviral therapeutics in securing a $7.9 million venture capital investment
- representing a German pharmaceutical manufacturer in its bulk supply as well as fill and finish processing arrangements in China
- representing an American medical technology company in connection with agency, distribution, consignment, equipment, HCO and HCP and other commercial agreements
- advising a Jordanian pharmaceutical company in relation to a licensing and supply agreement with an Indian generics company
Uusimmat Artikkelit
- legal updatesGlobal Health & Life Sciences Bulletin
- legal updatesGlobal Life Sciences & Healthcare Bulletin
- legal updatesGlobal Supply Chain Horizons - July 2025
- legal updatesGlobal Health and Life Sciences Newsletter Edition 12
Uusimmat Uutiset
legal updates
04. maaliskuuta 2026
Global Health & Life Sciences Bulletin
legal updates
03. joulukuuta 2025
Global Life Sciences & Healthcare Bulletin
legal updates
22. heinäkuuta 2025
Global Supply Chain Horizons - July 2025
legal updates
17. heinäkuuta 2025
Global Health and Life Sciences Newsletter Edition 12